G
GentiBio
Biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases
About GentiBio
GentiBio is a biotechnology startup focused on developing advanced therapies for autoimmune and inflammatory diseases. The company specializes in engineering regulatory T cells (Tregs), which are a type of immune cell that helps control the immune system and prevent it from attacking the body's own tissues. GentiBio's innovative platform aims to create stable and effective Tregs tailored for specific diseases, making them a promising solution for conditions like Type 1 Diabetes and other autoimmune disorders.
Read full description
The company operates in the biopharmaceutical market, targeting patients who suffer from autoimmune, alloimmune (immune response to non-self tissues), inflammatory, and allergic diseases. GentiBio's clients primarily include healthcare providers, research institutions, and potentially pharmaceutical companies looking for cutting-edge treatments.
GentiBio's business model revolves around the development and commercialization of its Treg therapies. The company generates revenue through partnerships, licensing agreements, and potentially direct sales of its therapeutic products once they receive regulatory approval. By focusing on scalable engineering and tissue targeting, GentiBio aims to simplify the manufacturing process and allow for patient-specific dosing, which enhances the efficacy and safety of its treatments.
The company has been recognized for its innovative approach and positive work environment, as evidenced by its inclusion in BioSpace's 2023 Best Places to Work. GentiBio's seasoned team brings deep expertise in cell therapy and synthetic immunology, positioning the company to overcome the key challenges in Treg therapeutics and deliver transformational therapies to patients in need.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Boston, United States
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Autoimmune, Inflammatory Diseases, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning GentiBio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2021 | $157M | $628M | Novartis Venture Fund · Children Hospital seattle · OrbiMed · JDRF T1D Fund | — |
| SEEDOther financing | Aug 2020 | $20M | $80M | RA Capital Management · Novartis Venture Fund · OrbiMed | — |
Growth signals
Latest recorded traffic for GentiBio is 3.2K monthly website visits, down 49.2% over the last three months. GentiBio's team declined 8.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 KyvernaKyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases |
Emeryville, United States | Operational | 174 | $170M | $350M |
 BiomXCustomized phage therapies to eradicate harmful bacteria in chronic diseases |
Ness Ziona, Israel | Operational | |||
 Silvia BioCellular analysis and media for biomanufacturing optimization. |
Sheffield, United Kingdom | Operational | |||
 Eywa BiotechBiosynthetic psychedelic APIs for mental health treatments |
Montevideo, Uruguay | Operational | |||
 GeneIIIA synthetic biology company integrating ergothioneine research and development, |
China | Operational | |||
 Wild MicrobesBiotech & Life Sciences |
Cambridge, United States | Operational | |||
 MoleculeMindA leading AI protein design platform company |
Haidian, China | Operational | |||
 Human Immunology BiosciencesBiotechnology company focused on developing therapies for immune-mediated diseases |
San Francisco, United States | Acquired |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
RA Capital Management
Novartis Venture Fund
OrbiMed
Series A4 investors entered at this stage
Matrix Capital Management
Children Hospital seattle
JDRF T1D Fund
Avidity Partners
Other known investors1 additional known investor
Migal Research Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GentiBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GentiBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.